NO20024924L - Anvendelse av bradykardiale substanser ved behandling av myokardiale sykdommer i forbindelse med hypertrofi og nyemedikamentkombinasjoner - Google Patents

Anvendelse av bradykardiale substanser ved behandling av myokardiale sykdommer i forbindelse med hypertrofi og nyemedikamentkombinasjoner

Info

Publication number
NO20024924L
NO20024924L NO20024924A NO20024924A NO20024924L NO 20024924 L NO20024924 L NO 20024924L NO 20024924 A NO20024924 A NO 20024924A NO 20024924 A NO20024924 A NO 20024924A NO 20024924 L NO20024924 L NO 20024924L
Authority
NO
Norway
Prior art keywords
hypertrophy
bradycardial
substances
treatment
connection
Prior art date
Application number
NO20024924A
Other languages
English (en)
Other versions
NO330311B1 (no
NO20024924D0 (no
Inventor
Juergen Dommgen
Brian Guth
Randolph Seidler
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20024924L publication Critical patent/NO20024924L/no
Publication of NO20024924D0 publication Critical patent/NO20024924D0/no
Publication of NO330311B1 publication Critical patent/NO330311B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20024924A 2000-04-13 2002-10-11 Bradykardiale substanser for behandling av myokardiale sykdommer som ledsages av hypertrofi. NO330311B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10018401A DE10018401A1 (de) 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
PCT/EP2001/004034 WO2001078699A2 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen

Publications (3)

Publication Number Publication Date
NO20024924L true NO20024924L (no) 2002-10-11
NO20024924D0 NO20024924D0 (no) 2002-10-11
NO330311B1 NO330311B1 (no) 2011-03-28

Family

ID=7638652

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024924A NO330311B1 (no) 2000-04-13 2002-10-11 Bradykardiale substanser for behandling av myokardiale sykdommer som ledsages av hypertrofi.

Country Status (33)

Country Link
US (2) US7208508B2 (no)
EP (2) EP1276476B1 (no)
JP (1) JP3905386B2 (no)
KR (1) KR20020089453A (no)
CN (1) CN1245963C (no)
AT (1) ATE330588T1 (no)
AU (2) AU7048401A (no)
BG (1) BG65816B1 (no)
BR (1) BR0109996A (no)
CA (2) CA2404120C (no)
CY (1) CY1105081T1 (no)
CZ (1) CZ300549B6 (no)
DE (2) DE10018401A1 (no)
DK (1) DK1276476T3 (no)
EA (1) EA006977B1 (no)
EE (1) EE05099B1 (no)
ES (1) ES2266216T3 (no)
HR (1) HRP20020815A2 (no)
HU (1) HU228387B1 (no)
IL (2) IL152103A0 (no)
ME (1) MEP45908A (no)
MX (1) MXPA02009935A (no)
NO (1) NO330311B1 (no)
NZ (1) NZ521934A (no)
PL (1) PL215235B1 (no)
PT (1) PT1276476E (no)
RS (1) RS51478B (no)
SI (1) SI1276476T1 (no)
SK (1) SK286075B6 (no)
TR (1) TR200202326T2 (no)
UA (1) UA78679C2 (no)
WO (1) WO2001078699A2 (no)
ZA (1) ZA200208162B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
ATE257384T1 (de) * 2002-07-25 2004-01-15 Boehringer Ingelheim Pharma Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
ME00479B (me) * 2003-01-31 2011-10-10 Daiichi Sankyo Co Ltd Lijek za profilaksu i tretman arterioskleroze i hipertenzije
JP5148296B2 (ja) * 2005-06-27 2013-02-20 第一三共株式会社 アンジオテンシンii受容体拮抗剤及びカルシウム拮抗剤含有医薬組成物
US20090247572A1 (en) * 2005-08-23 2009-10-01 Koichi Wada Agent for treating atrial fibrillation
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
PL2432452T3 (pl) 2009-05-20 2017-07-31 Boehringer Ingelheim Vetmedica Gmbh Farmaceutyczny pitny roztwór telmisartanu
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
KR101296743B1 (ko) * 2011-02-17 2013-08-20 한국과학기술연구원 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법
AU2012296925A1 (en) 2011-08-12 2014-02-06 Boehringer Ingelheim Vetmedica Gmbh Taste masked pharmaceutical composition
WO2014122248A1 (en) 2013-02-11 2014-08-14 Boehringer Ingelheim Vetmedica Gmbh Kit-of-parts
HRP20240703T1 (hr) 2017-07-07 2024-08-16 Boehringer Ingelheim Vetmedica Gmbh Telmisartan za profilaksu ili liječenje hipertenzije kod mačaka
KR102331806B1 (ko) 2020-07-20 2021-12-01 한림대학교 산학협력단 중증 지주막하출혈 진단용 바이오 마커
KR102398532B1 (ko) 2020-07-20 2022-05-13 한림대학교 산학협력단 중증 지주막하출혈 진단용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759125A (fr) 1969-11-19 1971-05-18 Boehringer Sohn Ingelheim Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US5175157A (en) 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3541811A1 (de) 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
RU2078536C1 (ru) * 1993-09-02 1997-05-10 Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией
WO1995008558A1 (en) 1993-09-24 1995-03-30 The Procter & Gamble Company Novel deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds
US5595987A (en) * 1994-07-22 1997-01-21 The Trustees Of Columbia University In The City Of New York Method of slowing ventricular arrhythmias using zatebradine
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
DE19741635A1 (de) 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
PT2322174E (pt) * 1998-07-10 2015-10-27 Novartis Pharma Gmbh Utilização combinada de valsartan e bloqueadores do canal de cálcio com objetivos terapêuticos
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
CA2435526A1 (en) 2002-07-25 2004-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography

Also Published As

Publication number Publication date
NZ521934A (en) 2007-05-31
RS51478B (sr) 2011-04-30
KR20020089453A (ko) 2002-11-29
CN1245963C (zh) 2006-03-22
BG65816B1 (bg) 2010-01-29
SK14582002A3 (sk) 2003-03-04
EE05099B1 (et) 2008-12-15
EP1276476A2 (de) 2003-01-22
EA006977B1 (ru) 2006-06-30
WO2001078699A3 (de) 2002-06-20
WO2001078699A2 (de) 2001-10-25
HU228387B1 (en) 2013-03-28
DE10018401A1 (de) 2001-10-25
MEP45908A (en) 2011-02-10
EP1276476B1 (de) 2006-06-21
US7208508B2 (en) 2007-04-24
CZ300549B6 (cs) 2009-06-10
PL215235B1 (pl) 2013-11-29
ZA200208162B (en) 2003-10-17
CY1105081T1 (el) 2009-11-04
SK286075B6 (sk) 2008-03-05
TR200202326T2 (tr) 2003-03-21
DE50110262D1 (de) 2006-08-03
MXPA02009935A (es) 2003-02-12
HRP20020815A2 (en) 2004-12-31
CA2404120C (en) 2008-01-22
CZ20023752A3 (cs) 2003-03-12
NO330311B1 (no) 2011-03-28
BR0109996A (pt) 2003-05-27
PT1276476E (pt) 2006-09-29
ES2266216T3 (es) 2007-03-01
IL152103A (en) 2008-07-08
EP1666042A2 (de) 2006-06-07
US20070155679A1 (en) 2007-07-05
DK1276476T3 (da) 2006-08-14
AU7048401A (en) 2001-10-30
EE200200590A (et) 2004-04-15
JP2003535050A (ja) 2003-11-25
SI1276476T1 (sl) 2006-10-31
ATE330588T1 (de) 2006-07-15
AU2001270484B2 (en) 2007-01-25
CN1422153A (zh) 2003-06-04
JP3905386B2 (ja) 2007-04-18
PL357827A1 (en) 2004-07-26
EA200201053A1 (ru) 2003-02-27
US20040014795A1 (en) 2004-01-22
BG107103A (bg) 2003-04-30
CA2575059A1 (en) 2001-10-25
NO20024924D0 (no) 2002-10-11
HUP0300917A3 (en) 2009-04-28
UA78679C2 (en) 2007-04-25
IL152103A0 (en) 2003-07-31
YU76902A (sh) 2006-05-25
EP1666042A3 (de) 2006-06-21
HUP0300917A2 (hu) 2003-08-28
CA2404120A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
NO20024924L (no) Anvendelse av bradykardiale substanser ved behandling av myokardiale sykdommer i forbindelse med hypertrofi og nyemedikamentkombinasjoner
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
MXPA02008770A (es) Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina.
TW200505901A (en) Muscarinic agonists
Biri et al. Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
EP1889614A3 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
PT1900362E (pt) Derivados de alfa-aminoamida úteis no tratamento de perturbações aditivas
GB2352972A (en) Use of dexmedetomidine for icu sedation
BR9910899A (pt) Compostos de ácido sulfÈnico ou sulfonilamino n-(hetero-aralquil)-azaeterocicliamida
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
Jefferson Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder)
BR0111982A (pt) Tratamento com apomorfina, de disfunção sexual induzida por droga anti depressão
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
RU2003130641A (ru) Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
US6214849B1 (en) Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans
BR9909476A (pt) Novos tratamentos para distúrbios nervosos
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
Fomaro et al. Clinical effects and plasma levels of lamotrigine in depressed outpatients. Preliminary results from an open trial
PL1514545T3 (pl) Zastosowanie tolperyzonu do leczenia skurczów narządów zbudowanych zasadniczo z mięśni gładkich
Higgins Reducing GI toxicity of NSAIDs: common goal, different approaches
UA38447A (uk) Спосіб лікування безбольової ішемії міокарда у хворих на артеріальну гіпертензію

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees